Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability
Bempedoic Acid Versus Statins in Primary-Prevention Patients With Suboptimal Statin Adherence: Effects on LDL-C Reduction and Tolerability
Bempedoic acid is an oral, non-statin LDL-cholesterol (LDL-C) lowering agent that inhibits ATP citrate lyase (ACL), upstream of HMG-CoA reductase (the enzyme inhibited by statins).
MDPI
+1
In patients with hypercholesterolemia who are unable to tolerate statins, or have sub-optimal statin adherence/tolerance, bempedoic acid has been shown to reduce LDL-C by ~20-30% (monotherapy) and more when added to other therapies (e.g., ezetimibe) (≈30-40%).
PubMed
In the large primary-prevention subgroup of the trial CLEAR Outcomes (statin-intolerant patients without prior cardiovascular event), bempedoic acid (180 mg daily) lowered LDL-C by ~21.3% and hs-CRP by ~21.5%. It also was associated with a significant reduction in major adverse cardiovascular events (MACE): hazard ratio 0.70 (95% CI 0.55-0.89) versus placebo over ~40 months.
PubMed +1
Regarding tolerability: muscle-related adverse events appear lower compared to statins (because bempedoic acid is activated only in the liver, not in skeletal muscle) and it appears generally well tolerated, but there are signals of increased uric acid/gout, elevated hepatic enzymes, and creatinine/renal effects.
MDPI
+1
Comparative cardiovascular benefit (when normalized per unit LDL-C reduction) suggests that bempedoic acid may yield similar relative risk reductions as statins, though absolute LDL-C lowering is less.
Mechanism: Bempedoic acid works by inhibiting ACL in the cholesterol-synthesis pathway; since the activating enzyme is present only in the liver (not muscle), the risk of muscle-related side-effects is diminished.
Frontiers
Indication/Use Case: Particularly useful in patients who (a) are at elevated cardiovascular risk (primary prevention or secondary), (b) cannot tolerate statins or have suboptimal adherence, and (c) need further LDL-C reduction beyond statin (or in place of statin) therapy.
Efficacy:
~20-30% LDL-C lowering as monotherapy in statin-intolerant patients. PubMed
+1
Additional benefit when combined with other therapies (e.g., ~30-40% reduction when combined with ezetimibe).
medicinejournal.in
In primary-prevention high-risk patients intolerant of statins: LDL-C reduction ~21% and hs-CRP ~21% with meaningful reduction in cardiovascular events.
PubMed +1
Tolerability/Safety:
Lower risk of muscle symptoms compared to statins. PubMed
+1
Known adverse signals: hyperuricemia/gout, elevated liver enzymes, possibly increased creatinine/renal changes.
JAMA Network +1
Comparison with Statins:
Statins typically reduce LDL-C by much larger margins (30-50%+ depending on dose/intensity). Bempedoic acid's LDL-C reduction is more modest in comparison.
However, when looking at the risk reduction per unit LDL-C lowering, bempedoic acid appears to yield similar relative benefits as statins.
American College of Cardiology
+1
Clinical Implication: In patients with suboptimal statin use (due to intolerance, non-adherence, or contraindication), bempedoic acid offers a viable adjunct or alternative lipid-lowering strategy in the primary prevention setting.
Limitations:
Not a direct head-to-head trial of bempedoic acid versus statins in the scenario of suboptimal statin adherence.
Absolute reduction in LDL-C is lower than high-intensity statins, so expectations must be calibrated accordingly.
Long-term safety in wider populations continues to be monitored.
Cost and accessibility may vary by region; local cost-effectiveness needs evaluation.
Inclusion Criteria
Adults aged ≥40 years with no established ASCVD (no prior myocardial infarction, stroke, or acute coronary syndrome).
Indicated for lipid-lowering therapy (LDL-C ≥130 mg/dL or 10-year ASCVD risk
≥7.5%).
Documented history of poor statin adherence, defined as:
Willingness to provide written informed consent. Exclusion Criteria
Established ASCVD (secondary prevention).
Severe hepatic impairment (ALT or AST >3× upper limit of normal).
Severe renal impairment (eGFR <30 mL/min/1.73 m²).
Pregnancy, breastfeeding, or women of childbearing potential not using contraception.
Current or planned treatment with PCSK9 inhibitors, fibrates, or niacin.
Known hypersensitivity to study drugs or excipients.
sohaib-ashraf@outlook.com+923334474523